These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27307405)

  • 21. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
    Shimizu T; Harada K; Kataoka Y
    Acta Vet Scand; 2013 May; 55(1):37. PubMed ID: 23634902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
    Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
    Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wound contamination and antimicrobial susceptibility of bacteria cultured during total ear canal ablation and lateral bulla osteotomy in dogs.
    Vogel PL; Komtebedde J; Hirsh DC; Kass PH
    J Am Vet Med Assoc; 1999 Jun; 214(11):1641-3. PubMed ID: 10363095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of antibacterial activities of cephalosporin antibiotics: cefazolin, cephaloridine, cephalothin, and cephalexin.
    Hsieh WC; Ho SW
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1975 Mar; 8(1):1-11. PubMed ID: 1097210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.
    Lees P
    J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8.
    Wetzstein HG; Hallenbach W
    J Antimicrob Chemother; 2011 Dec; 66(12):2801-8. PubMed ID: 21948964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs.
    Petersen SW; Rosin E
    Vet Surg; 1995; 24(4):347-51. PubMed ID: 7571387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial resistance of Staphylococcus pseudintermedius isolates from healthy dogs and dogs affected with pyoderma in Japan.
    Onuma K; Tanabe T; Sato H
    Vet Dermatol; 2012 Feb; 23(1):17-22, e5. PubMed ID: 21745248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.
    Wetzstein HG
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4166-73. PubMed ID: 16189094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro efficacy of the essential oil from Leptospermum scoparium (manuka) on antimicrobial susceptibility and biofilm formation in Staphylococcus pseudintermedius isolates from dogs.
    Song CY; Nam EH; Park SH; Hwang CY
    Vet Dermatol; 2013 Aug; 24(4):404-8, e87. PubMed ID: 23772881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of cefazolin and ampicillin.
    Datta SK
    Kathmandu Univ Med J (KUMJ); 2004; 2(1):47-8. PubMed ID: 19780288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens.
    Blondeau JM; Fitch SD
    Microorganisms; 2024 May; 12(5):. PubMed ID: 38792823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships between in vitro susceptibility and efficacy in experimental mouse infection-protection assay of cefazolin and cephalothin using Escherichia coli strains.
    Uri JV; Actor P; Phillips L; Guarini JR; Weisbach JA
    Chemotherapy; 1976; 22(5):313-8. PubMed ID: 780071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma.
    Ganiere JP; Medaille C; Mangion C
    J Vet Med B Infect Dis Vet Public Health; 2005 Feb; 52(1):25-31. PubMed ID: 15702997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial resistance in Staphylococcus pseudintermedius in the Norwegian dog population.
    Norström M; Sunde M; Tharaldsen H; Mørk T; Bergsjø B; Kruse H
    Microb Drug Resist; 2009 Mar; 15(1):55-9. PubMed ID: 19216647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility in vitro of canine methicillin-resistant and -susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma.
    Clark SM; Loeffler A; Bond R
    J Antimicrob Chemother; 2015 Jul; 70(7):2048-52. PubMed ID: 25749003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sensitivity of nanoparticlized cefazolin sodium to the bacteria in vitro].
    Zou L; Fan XG; Gui H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 30(3):318-20. PubMed ID: 16045023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of canine-specific minocycline and doxycycline susceptibility breakpoints for meticillin-resistant Staphylococcus pseudintermedius isolates from dogs.
    Hnot ML; Cole LK; Lorch G; Papich MG; Rajala-Schultz PJ; Daniels JB
    Vet Dermatol; 2015 Oct; 26(5):334-8, e70-1. PubMed ID: 26216025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats.
    Silley P; Stephan B; Greife HA; Pridmore A
    J Antimicrob Chemother; 2007 Nov; 60(5):999-1003. PubMed ID: 17872918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
    Blondeau JM; Shebelski SD; Hesje CK
    Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.